MALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targetingMALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting

NexEos Bio Announces FDA Clearance of IND Application to Proceed to Phase II/III Trial of NTX-1024 in Vernal Keratoconjunctivitis

2026/02/20 00:01
Okuma süresi: 3 dk
Bu içerikle ilgili geri bildirim veya endişeleriniz için lütfen [email protected] üzerinden bizimle iletişime geçin.

MALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting eosinophil-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared NexEos’s Investigational New Drug (IND) Application to proceed to a Phase II/III clinical trial of NTX-1024 for the treatment of patients with the rare disease, vernal keratoconjunctivitis (VKC). The planned Phase II/III trial is a single, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of NTX-1024 ophthalmic solution in patients with VKC.

This is on the heels of the positive results reported from an open-label, investigator-initiated study evaluating the efficacy, safety, and tolerability of NTX-1024 eye drops in adults with VKC. The study was conducted in Mexico and enrolled 15 patients with mild to moderate VKC who received NTX-1024 four times daily over a four-week period. Treatment led to significant improvement in patient-reported symptoms such as itching and quality of life, along with reductions in clinical signs of inflammation, including hyperemia and corneal fluorescein staining. NTX-1024 was also found to be safe and well-tolerated.

This marks the first clinical study to evaluate NTX-1024 in VKC, a rare and severe eosinophil-driven ocular condition that can lead to irreversible ocular damage, including vision loss, if left untreated. These results reinforce the therapeutic potential of NTX-1024 in VKC and have prompted NexEos to pursue further clinical development.

In addition, on January 16, 2026, the FDA granted Orphan Drug Designation to NTX-1024 for VKC.

“Clearance of our IND application, which included data from our open-label investigator-initiated study in Mexico, is an important and meaningful step for the program,” said Steve Tullman, CEO and Chairman of NexEos. “We are excited to advance clinical development of NTX-1024, which would be the first, ophthalmic therapeutic to neutralizes eosinophil cationic protein to reduce inflammation in rare forms of Allergic Conjunctivitis – Vernal Keratoconjunctivitis (VKC) and Atopic Keratoconjunctivitis (AKC). We are on track to initiate our Phase II/III clinical trial by the second half of this year, taking us closer to our objective of delivering a best-in-class therapeutic option to patients with VKC.”

About Vernal Keratoconjunctivitis (VKC)

VKC is a rare, chronic, and vision-threatening ocular inflammatory disease that is predominantly eosinophil-mediated. Activated eosinophils release toxic granule proteins, including eosinophil major basic protein-1 (eMBP1), resulting in damage to the ocular surface (Sacchetti, et al. 2021). VKC primarily affects children although approximately 10% of cases persist into adulthood (Di Zazzo A 2024). Uncontrolled VKC can result in severe ocular damage and permanent vision loss (Vichyanond, et al. 2014).

About NTX-1024 (gleceparin sodium)

NTX-1024 is a novel, topical ophthalmic solution targeting eosinophil cationic protein mediated inflammation in rare forms of allergic conjunctivitis, including VKC and AKC. NTX-1024 has completed proof of concept in VKC, received ODD approval, and now has FDA clearance of its IND application to advance to a Phase II/III clinical trial in VKC. NTX-1024 is the first therapeutic successfully targeting neutralization of eosinophil cationic proteins. Finally, NTX-1024 has the potential to be the first drug to be disease-modifying and steroid-sparing in VKC and AKC.

About NexEos Bio

NexEos Bio (www.nexeosbio.com) is a privately held medical diagnostics and therapeutics company based in Malvern, Pennsylvania, dedicated to improving the detection, diagnosis, treatment and life-long management of patients living with chronic, eosinophil-related inflammatory diseases. Through the licensing, development and commercialization of novel technologies, NexEos Bio is bringing new tools and therapies to market that address the unmet needs of patients suffering from eosinophil-related diseases.

Contacts

For more Information, please send inquiries to: [email protected]

Piyasa Fırsatı
NuNet Logosu
NuNet Fiyatı(NTX)
$0.00401
$0.00401$0.00401
-0.98%
USD
NuNet (NTX) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen [email protected] ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Top White House official warns aides against selling Trump 'rose-colored view' of Iran war

Top White House official warns aides against selling Trump 'rose-colored view' of Iran war

After returning to the White House on January 20, 2025, President Donald Trump made sure his second administration was much different from his first. Trump clashed
Paylaş
Alternet2026/04/03 01:59
Vacation plans implode across America as Trump massacres the economy

Vacation plans implode across America as Trump massacres the economy

More and more Americans are finding that not even a nice vacation can save them from President Donald Trump's chaos.According to a Thursday report from Bloomberg
Paylaş
Alternet2026/04/03 02:22
$5 billion floods into XRP in a day; Here’s why

$5 billion floods into XRP in a day; Here’s why

The post $5 billion floods into XRP in a day; Here’s why appeared on BitcoinEthereumNews.com. XRP extended its rally on September 18, adding more than $5 billion in market value in under 24 hours. The token climbed from $3 to $3.10, pushing its market cap from $180.47 billion to $185.79 billion at the time of publication. Trading activity also surged, with 24-hour volume up 57% to $7.21 billion, as per data retrieved by Finbold from CoinMarketCap. The move coincides with confirmation that the REX-Osprey XRP ETF ($XRPR) will debut today after earlier delays. Unlike traditional spot ETFs, $XRPR will operate under a Registered Investment Company (RIC) structure, holding XRP alongside cash and Treasuries. Analysts say the product offers three key signals: it provides regulated exposure for U.S. investors without requiring direct XRP custody, it highlights growing institutional acceptance despite SEC hesitation on other ETF applications, and it is already sparking ETF-driven trading activity in spot markets. Sustaining daily volumes of over $200 million will be a key test in the weeks ahead. XRP technical analysis From a technical perspective, XRP has broken above its 7-day SMA ($3.06) and the 23.6% Fibonacci retracement ($3.07). The MACD histogram flipped positive (+0.0223), while the RSI (57.09) suggests room to extend without tipping into overbought conditions. Immediate resistance sits at $3.18, with a clean break opening the door to the $3.48 target at the 127.2% Fibonacci extension. XRP’s latest move combines ETF-driven institutional interest, technical resilience, and altcoin market tailwinds. While the ETF structure may not drive direct XRP demand as aggressively as a spot product, its novelty could attract new pools of capital and further legitimize the asset in U.S. markets. Source: https://finbold.com/5-billion-floods-into-xrp-in-a-day-heres-why/
Paylaş
BitcoinEthereumNews2025/09/18 19:32

Trade GOLD, Share 1,000,000 USDT

Trade GOLD, Share 1,000,000 USDTTrade GOLD, Share 1,000,000 USDT

0 fees, up to 1,000x leverage, deep liquidity